• **Name:** Tetsuya Nakatsura

• **Current Position & Affiliation:** Chief,
Division of Cancer Immunotherapy,
Exploratory Oncology Research and
Clinical Trial Center,
National Cancer Center

• **Country:** Japan

• **Educational Background:**
1992 M.D. Kumamoto University, Faculty of Medicine
2001 Ph.D. Kumamoto University Graduate School of Medical Sciences

• Professional Experience:
1992-1994 Department of Surgery II, Kumamoto University School of Medicine
1994-1997 National Cancer Center Hospital, East
2000-2001 Research Fellow of the Japan Society for the Promotion of Science
2001-2005 Assistant Professor, Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University
2005-2012 Section Head, Section for Cancer Immunotherapy, Research Center for Innovative Oncology, National Cancer Center Hospital East
2012-2013 Chief, Division of Cancer Immunotherapy, Research Center for Innovative Oncology, National Cancer Center Hospital East
2013- Chief, Division of Cancer Immunotherapy, Exploratory Oncology & Clinical Trial Center, National Cancer Center

• **Professional Organizations:**
Chairman of Japan Research Association for Immunotherapeutics,
a Director of The Japanese Association of Cancer Immunology,
a Director of Japanese Society for Molecular Tumor Marker Research,
a Councilor of The Japanese Cancer Association,
an Active Member of The American Association for Cancer Research.

• **Main Scientific Publications:**
Kinoshita H, Takenouchi K, Tsukamoto N, Ohnuki K, Suzuki T, Nakatsura T. Identification of 68 HLA-A24 and -A2-restricted cytotoxic T lymphocyte-inducing peptides derived from 10 common cancer-specific antigens frequently expressed in various solid cancers. Neoplasia. 2025 Mar;61:101135.
Nakatsura T, Takenouchi K, Kataoka J, Ito Y, Kikuchi S, Kinoshita H, Ohnuki K, Suzuki T, Tsukamoto N. Expression Profiles of Five Common Cancer Membrane Protein Antigens Collected for the Development of Cocktail CAR-T Cell Therapies Applicable to Most Solid Cancer Patients. Int J Mol Sci. 2025 Feb 27;26(5):2145.

Taniguchi M, Mizuno S, Yoshikawa T, Fujinami N, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Nakatsura T. Peptide vaccine as an adjuvant therapy for glypican-3 positive hepatocellular carcinoma induces peptide specific CTLs and improves long prognosis. Cancer Science. 111(8)2747-2759, 2020 Aug

Tsuchiya N, Hosono A, Yoshikawa T, Shoda K, Nosaka K, Shimomura M, Hara J, Nitani C, Manabe A, Yoshihara H, Hosoya Y, Kaneda H, Kinoshita Y, Kohashi K, Yoshimura K, Fujinami N, Saito K, Mizuno S, Nakatsura T. Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors. OncoImmunology. 7(1):e1377872. 2017

Sawada Y, Yoshikawa T, Ofuji K, Yoshimura M, Tsuchiya N, Takahashi M, Nobuoka D, Gotohda N, Takahashi S, Kato Y, Konishi M, Kinoshita T, Ikeda M, Nakachi K, Yamazaki N, Mizuno S, Takayama T, Yamao K, Uesaka K, Furuse J, Endo I, Nakatsura T. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. OncoImmunology, 5:e1129483, 2016

Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Takayama T, Yamao K, Uesaka K, Furuse J, Kinoshita T, Nakatsura T. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res, 18:3686-3696, 2012

Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res, 12:2689-2697, 2006